A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)

NCT05616754 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
BIOLOGICAL: Recombinant Novel Coronavirus Protein Vaccine (CHO cells)

Sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.